Huub H van Rossum 1,2 , Daan van den Broek 1 Show Affiliations »
Abstract
BACKGROUND: In recent years there has been renewed interest in patient-based real-time quality control (PBRTQC) techniques. This interest has been stimulated by the availability of new optimization and validation methods. Only a limited amount of research has focused on investigating the true operational value of PBRTQC. Therefore, we have evaluated the performance and value of recently implemented patient moving average quality control (MA QC) procedures. METHODS: The MA QC settings and protocols were as previously described (Clin Chem Lab Med 2019;57:1329-38) and included MA QCs for 10 chemistry and 6 hematological tests, all performed on duplicate analyzer systems. All MA QC alarms that occurred during the first 10 months of routine clinical application were investigated for assay-specific alarm rate and occurrence in time. Furthermore, the causes of these MA QC alarms were investigated, and alarm relevance was determined on the basis of total allowable bias (TBa) and error (TEa) derived from biological variations. RESULTS: During the 10-month period, 202 individual MA QC alarms occurred, resulting in an overall MA QC alarm rate of 0.030% and a frequency of 4.67 per week. Most alarms were triggered by sodium MA QC. Based on all available fully executed and documented MA QC alarm work-ups, MA QC detected errors that in 26.0% of the alarms exceeded the TBa and in 13.7% the TEa. In 9.2% of the alarms, MA QC alarming triggered instant (technical) corrections. CONCLUSIONS: Routine clinical application of MA QC is feasible with maintaining a manageable number of alarms and enabling detection of relevant analytical errors. © American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.
BACKGROUND: In recent years there has been renewed interest in patient -based real-time quality control (PBRTQC) techniques. This interest has been stimulated by the availability of new optimization and validation methods. Only a limited amount of research has focused on investigating the true operational value of PBRTQC. Therefore, we have evaluated the performance and value of recently implemented patient moving average quality control (MA QC) procedures. METHODS: The MA QC settings and protocols were as previously described (Clin Chem Lab Med 2019;57:1329-38) and included MA QCs for 10 chemistry and 6 hematological tests, all performed on duplicate analyzer systems. All MA QC alarms that occurred during the first 10 months of routine clinical application were investigated for assay-specific alarm rate and occurrence in time. Furthermore, the causes of these MA QC alarms were investigated, and alarm relevance was determined on the basis of total allowable bias (TBa ) and error (TEa) derived from biological variations. RESULTS: During the 10-month period, 202 individual MA QC alarms occurred, resulting in an overall MA QC alarm rate of 0.030% and a frequency of 4.67 per week. Most alarms were triggered by sodium MA QC. Based on all available fully executed and documented MA QC alarm work-ups, MA QC detected errors that in 26.0% of the alarms exceeded the TBa and in 13.7% the TEa. In 9.2% of the alarms, MA QC alarming triggered instant (technical) corrections. CONCLUSIONS: Routine clinical application of MA QC is feasible with maintaining a manageable number of alarms and enabling detection of relevant analytical errors. © American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Entities: Chemical
Disease
Species
Keywords:
AoN; Moving average; PBRTQC; analytical quality control; average of normals; quality assurance; quality control
Year: 2020
PMID： 32533149 DOI： 10.1093/jalm/jfaa071
Source DB: PubMed Journal: J Appl Lab Med ISSN： 2475-7241